SOCS1-derived peptide administered by eye drops prevents retinal neuroinflammation and vascular leakage in experimental diabetes

Otros/as autores/as

[Hernández C, Bogdanov P, Sampedro J, Solà-Adell C, García-Ramírez M, Simó R] Grup de Diabetis i Metabolisme, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Gómez-Guerrero C] Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Renal, Vascular and Diabetes Research Lab, Instituto de Investigacion Sanitaria-Fundación Jimenez Diaz (IIS-FJD), Madrid, Spain. Autonoma University of Madrid (UAM), Madrid, Spain. [Espejo, C] Recerca en Neuroimmunologia clínica, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain.

Vall d'Hebron Barcelona Hospital Campus

Fecha de publicación

2020-02-04T13:37:12Z

2020-02-04T13:37:12Z

2019-07-24



Resumen

Diabetic retinopathy; Neuroinflammation; Suppressors of cytokine signaling


Retinopatía diabética; Neuroinflamación; Supresores de señalizadores de citoquinas


Retinopatia diabètica; Neuroinflamació; Supressors de senyalitzadors de citoquines


Current treatments for diabetic retinopathy (DR) target late stages when vision has already been significantly affected. Accumulating evidence suggests that neuroinflammation plays a major role in the pathogenesis of DR, resulting in the disruption of the blood-retinal barrier. Suppressors of cytokine signaling (SOCS) are cytokine-inducible proteins that function as a negative feedback loop regulating cytokine responses. On this basis, the aim of the present study was to evaluate the effect of a SOCS1-derived peptide administered by eye drops (2 weeks) on retinal neuroinflammation and early microvascular abnormalities in a db/db mouse model. In brief, we found that SOCS1-derived peptide significantly reduced glial activation and neural apoptosis induced by diabetes, as well as retinal levels of proinflammatory cytokines. Moreover, a significant improvement of electroretinogram parameters was observed, thus revealing a clear impact of the histological findings on global retinal function. Finally, SOCS1-derived peptide prevented the disruption of the blood-retinal barrier. Overall, our results suggest that topical administration of SOCS1-derived peptide is effective in preventing retinal neuroinflammation and early microvascular impairment. These findings could open up a new strategy for the treatment of early stages of DR.


This study was supported by grants from the Ministerio de Economia y Competitividad (PI16/00541, SAF2015-63696-R, PI14/00386, PI17/01495 and DTS-2017/00203). Cristina Sola-Adell is a recipient of a Predoctoral Research Grant from MINECO (BES-2013-064944). Joel Sampedro is a recipient of a Predoctoral Research Grant from AGAUR.

Tipo de documento

Artículo


Versión publicada

Lengua

Inglés

Publicado por

MDPI

Documentos relacionados

International Journal of Molecular Sciences;20(15)

https://www.mdpi.com/1422-0067/20/15/3615

Citación recomendada

Esta citación se ha generado automáticamente.

Derechos

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

Este ítem aparece en la(s) siguiente(s) colección(ones)